Skip to content
Visit the website
Organization profile · Media, data and longevity ecosystem

Longevity.Technology

Publisher · intelligence provider · directory · events · For readers, investors, operators, clinics, sponsors and sector participants

Longevity news and interviews, DLT biotech intelligence for company teams, clinic discovery, and partnership routes for sponsors and advertisers.

Open access
News + podcast
Professional data
DLT demo-led
Paid reports
From
Legal operator
First Longevity Ltd
Programs, prices, company records and coverage checkedReviewed

Who they are

Overview

Longevity.Technology is the trading name of First Longevity Ltd, a UK company incorporated in 2019. Its free side covers daily longevity news, interviews, the UNLOCKED podcast and a clinic directory. Its professional product is DLT, a demo-led data platform that tracks longevity biotech companies and assets; it is quoted for biotech and pharma teams and, per its pricing page, is not offered to investors. Clinics can register for the directory, and sponsors and advertisers work with the team through inquiry.

At a glance

Legal operator
First Longevity Ltd
Active UK private company 12345643; the public brand is Longevity.Technology.
Open access
Longevity.Technology news + daily briefing · UNLOCKED podcastLongevity.Technology news + daily briefingUNLOCKED podcast
Current articles, the daily email briefing and UNLOCKED episodes are available through the public site.
Professional products
DLT + bespoke intelligenceDLTbespoke intelligence
Sales-led. Biotech teams are quoted annual or quarterly named-seat subscriptions and large pharma custom terms; DLT is not available to investors.
Published paid products
2023 report · first-half 2024 report · research subscription2023 reportfirst-half 2024 reportresearch subscription
Older research products sold separately from DLT; confirm current availability and price on each purchase page.
Clinic pathway
Clinic discovery + free registrationfree registration
The directory serves people researching clinics and organizations seeking listing visibility.
Latest verified event
The Longevity Show · June 2026
The first edition has concluded; no future ticketed edition was confirmed in this review.

Company claims

  • Understanding the longevity sector

    Longevity.Technology presents its media as a resource for professionals, innovators and investors exploring the science, technology and business of longevity.

  • Searchable longevity intelligence

    Longevity.Technology says its DLT data platform brings company information, signals and trends from across longevity into one searchable dataset.

Access and commercial model

Published prices and inquiry routes

Paid reports

News and podcast access are free; DLT and commercial services use direct inquiry.

From

DLT is the current intelligence platform; the separately sold investment reports cover 2023 and the first half of 2024.

  • Daily briefing

    Public reading and newsletter signup are available from the editorial site.

    Free
    Read news and join the daily briefing
  • Clinic registration

    Ask how listings are reviewed, ranked, updated and connected to inquiries before relying on the channel.

    Free
    Review clinic registration
  • UNLOCKED

    Episodes are publicly accessible from the podcast page and linked listening platforms.

    Free
    Explore UNLOCKED
  • First-half 2024 report

    Verify that the historical coverage period matches the decision you are making now.

    View the first-half 2024 report
  • 2023 annual report

    A historical report sold separately from DLT and current custom research.

    View the 2023 annual report
  • DLT platform

    Biotech teams: pricing on request for an annual or quarterly named-seat subscription. Large pharma: custom terms. Not available to investors. Ask for seats, datasets, export rights, onboarding and support in one proposal.

    Quoted by tier
    Explore DLT intelligence
  • Bespoke intelligence

    Define the research question, source coverage, method, named deliverables, review cycle and reuse rights.

    Custom quote
    Review bespoke intelligence
  • Research subscription

    An older investment-research subscription sold separately from DLT. Its purchase page could not be rechecked on 26 September 2026; confirm the current price and checkout there before buying.

    Legacy product · price to confirm
    Review research subscription
  • Advertising and sponsorship

    Request the audience definition, placement, duration, labeling, reporting and cancellation terms for the proposed campaign.

    Enquiry
    Review advertising and sponsorship
Current versus legacy

DLT is the current intelligence platform. The 2023 and 2024 reports and their investment subscription are older products with separate access terms.

DLT eligibility

The DLT pricing page says the platform is not available to investors. Investor readers can still use the free news and podcast and the separately sold reports.

Event access

The June 2026 Longevity Show has concluded, so its former ticket route is not presented as a current purchase option.

First-party product, report, registration, podcast and advertising pages checked 30 August 2026; DLT pricing and eligibility rechecked 25–26 September 2026.

What each program delivers

Publishing, intelligence and participation

Longevity.Technology publishes news and interviews alongside research products, a data platform, directories and events.

  • Articles + newsletter

    Editorial publishing

    Daily news, interviews, analysis and email distribution cover science, companies, clinics, products, investment and policy.

  • Companies + assets

    DLT market intelligence

    Longevity.Technology reports coverage of 728 biotech companies, 3,176 aging-disease assets and 1,585 gerotherapeutic assets, with continuous signal monitoring. It describes a review workflow using AI, validators and human reviewers.

  • Reports + custom briefs

    Commercial research

    Historical reports remain available individually, while DLT promotes generated briefs, market maps, diligence output and bespoke intelligence.

  • Listings + inquiries

    Longevity Clinics directory

    The public directory presents clinic profiles and prices, while a separate registration route invites clinics to seek inclusion and inquiries.

  • Interviews + gatherings

    UNLOCKED and events

    The podcast publishes public interviews and news roundups. The first Longevity Show brought attendees, speakers, exhibitors and sponsors together in London in June 2026.

Who can access what

Access by program

Public content is open; professional products and commercial participation use product-specific purchase, registration or inquiry routes.

Editorial
Read current articles or join the daily email briefing from the main site.
UNLOCKED
Episodes and news roundups are publicly accessible.
DLT
Biotech and pharma teams can book a demo and request a quote; the platform is not available to investors.
Reports
2023 report + first-half 2024 report2023 reportfirst-half 2024 report
Both historical investment reports remain individually priced.
Clinic directory
Clinics can submit the first-party registration route for review.
Advertising + sponsorship
Scope, inventory, audience and rates are confirmed directly.

Ownership and public leadership

Who operates the organization

First-party leadership names align with the current statutory director record for First Longevity Ltd.

Founder and chief executive officer

Phil Newman

Current director and person with significant control, holding more than 50% but less than 75% of shares and voting rights.

Non-executive chair

George Sutherland

Named on the organization site and recorded as a current First Longevity Ltd director.

Non-executive director

Tom Britton

Named on the organization site and recorded as a current First Longevity Ltd director.

Advertising contact

Dev Heaton

Named on the current advertising page for commercial inquiries.

Clinics initiative

Manjit Sareen

Named in first-party material for the clinic-directory program.

UNLOCKED co-host

Dr Nina Patrick

Named on the podcast page; this program role is not presented as a company-director position.

What can be checked

Product and procurement record

A newsroom and a professional data platform run by the same UK operator, with DLT sold to biotech and pharma teams rather than investors.

What sets it apart

  • Biotech data built for company teams: DLT reports coverage of 728 biotech companies, 3,176 aging-disease assets and 1,585 gerotherapeutic assets, with search, alerts, exports and a structured-data copilot.

  • Newsroom and data under one operator: daily reporting, the UNLOCKED podcast and a clinic directory run alongside DLT, all from First Longevity Ltd since 2019. Companies House names Phil Newman as the person with significant control.

  • An industry source for major outlets: The Wall Street Journal, The New York Times, Bloomberg and Fortune have cited Longevity.Technology or Phil Newman in their longevity coverage.

Confirm before buying

  • DLT is quoted per team: biotech buyers choose an annual or quarterly named-seat subscription, and large pharma buyers receive custom terms. The platform is not available to investors.

  • The older research subscription could not be rechecked on 26 September 2026; confirm its current price and checkout before buying.

  • The paid investment reports cover 2023 and the first half of 2024; check that the period fits the decision you are making.

Reporting and company history

Press and announcements

Mainstream coverage establishes the organization's visibility as an industry source. Company announcements are listed separately because they document what First Longevity said and when.

Independent coverage and industry citations

Most major-outlet items use Longevity.Technology or Phil Newman as a source within broader reporting rather than reviewing the company or DLT directly.

First-party announcements

These items establish company statements and launches, not independent validation of product performance or partnership impact.

Common questions

Frequently asked questions

Transparency

Transparency and sources

Researched by Longevity.io

Reviewed

Directory listings are for informational purposes only. Inclusion does not constitute endorsement. Verify credentials and qualifications independently.

Keep exploring

Your Longevity Blueprint

Build your starting plan.

A few short questions, about two minutes. The Blueprint recommends where to start and explains why.

Build my Blueprint